Perrigo's generic Voltaren gets FDA approval
Perrigo has received the Food and Drug Administration’s clearance for diclofenac sodium topical gel, 1%. The company said the generic of GlaxoSmithKline's Voltaren gel would launch within the next two months.
Voltaren gel, 1%, had a market value of about $350 million for the 12 months ending March 2019, according to IQVIA.
"This is our fifth extended topical ANDA approval in 2019 which demonstrates our commitment to delivering high quality affordable extended topical products for patients in important categories. Our strategic partnership with Water Street enables us to accelerate this commitment and lower the cost of healthcare for consumers," said Sharon Kochan, Perrigo executive vice president and president of Rx pharmaceuticals.
Voltaren gel, 1%, had a market value of about $350 million for the 12 months ending March 2019, according to IQVIA.
"This is our fifth extended topical ANDA approval in 2019 which demonstrates our commitment to delivering high quality affordable extended topical products for patients in important categories. Our strategic partnership with Water Street enables us to accelerate this commitment and lower the cost of healthcare for consumers," said Sharon Kochan, Perrigo executive vice president and president of Rx pharmaceuticals.